tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
PremiumCompany AnnouncementsRapport Therapeutics’ New Study on RAP-219: A Potential Game-Changer for Epilepsy Treatment
12d ago
Premium
Company Announcements
Rapport Therapeutics’ RAP-219 Study: A Potential Game-Changer for Bipolar I Disorder
12d ago
3 Best Stocks to Buy Now, 9/16/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 9/16/2025, According to Top Analysts
2M ago
Rapport Therapeutics 9.62M share Secondary priced at $26.00
PremiumThe FlyRapport Therapeutics 9.62M share Secondary priced at $26.00
2M ago
Closing Bell Movers: Nebius up over 40% on Microsoft deal
Premium
The Fly
Closing Bell Movers: Nebius up over 40% on Microsoft deal
2M ago
Premium
Company Announcements
Rapport Therapeutics Terminates Common Stock Prospectus
2M ago
Rapport Therapeutics price target raised to $34 from $31 at H.C. Wainwright
PremiumThe FlyRapport Therapeutics price target raised to $34 from $31 at H.C. Wainwright
2M ago
Premium
Company Announcements
Rapport Therapeutics Reports Positive Phase 2a Trial Results
2M ago
Rapport Therapeutics says Phase 2a trial of RAP-219 met primary endpoint
Premium
The Fly
Rapport Therapeutics says Phase 2a trial of RAP-219 met primary endpoint
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100